Drugs / PTR-01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03752905 | Jan 2019 → Nov 2020 | recessive dystrophic epidermolysis bullosa | Phoenix Tissue Repair, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05143190 | Dec 2021 → Jun 2022 | recessive dystrophic epidermolysis bullosa | Phoenix Tissue Repair, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04599881 | Oct 2020 → Aug 2021 | recessive dystrophic epidermolysis bullosa | Phoenix Tissue Repair, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma affiliate phoenix tissue repair announces positive results from phase 2 trial of ptr-01, a protein replacement therapy for the treatment of recessive dystrophic epidermolysis bullosa (rdeb) bridgebio.com ↗
Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments |
| 2020-05-13 | Eidos Therapeutics, a BridgeBio company | Results bridgebio pharma’s phoenix tissue repair provides updates to its recessive dystrophic epidermolysis bullosa (rdeb) program and announces new leadership appointments bridgebio.com ↗
Based on an interim review of data from the first three cohorts of trial participants, PTR-01 has been well tolerated in all nine patients, and there have been no treatment-related serious adverse events at any dose. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma affiliate phoenix tissue repair announces positive results from phase 2 trial of ptr-01, a protein replacement therapy for the treatment of recessive dystrophic epidermolysis bullosa (rdeb) bridgebio.com ↗ |
| 2020-05-13 | Eidos Therapeutics, a BridgeBio company | bridgebio pharma’s phoenix tissue repair provides updates to its recessive dystrophic epidermolysis bullosa (rdeb) program and announces new leadership appointments bridgebio.com ↗ |
| 2019-02-22 | Eidos Therapeutics, a BridgeBio company | phoenix tissue repair doses first patient in phase 1/2 clinical trial of ptr-01 (bbp-589) for treatment of recessive dystrophic epidermolysis bullosa (rdeb) bridgebio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTR-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04599881 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human collagen 7 (rC7)” NCT03752905 ↗ |
| Route | Intravenous | “Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.” NCT03752905 ↗ |